\nThe amended and restated facility refinances the company\u2019s existing debt and allows access to additional capital to support ongoing operations and future strategic growth initiatives.<\/p>\n
\n\u201cThis strengthens our capital structure by extending our maturity and enhancing our financial flexibility,\u201d said Sandra Harris, Chief Financial Officer of Establishment Labs. \u201cThe initial tranche fully refinances our existing debt until 2031 and the additional capacity provides flexibility to support future strategic initiatives. Our business continues to accelerate, and we expect to be positive free cash flow in the second half of this year with substantial growth ahead of us. Oaktree\u2019s continued support reflects their long-standing confidence in our business, and we are very pleased to continue our collaboration with them.\u201d<\/p>\n
\n\u201cOaktree is proud to continue its support of Establishment Labs,\u201d said Aman Kumar, Co-Portfolio Manager for Oaktree\u2019s Life Sciences Lending platform. \u201cOver the past four years, we have witnessed the company\u2019s commitment to strong fundamentals and sustainable growth, supported by important innovation in breast aesthetics and reconstruction and the rapid market expansion of Motiva implants in the United States. We look forward to continuing our partnership with Establishment Labs and supporting the management team in its next phase of growth.\u201d<\/p>\n
\nKey Terms of the Credit Facility:<\/p>\n
- \n
- \n$300 million senior secured first-lien term loan with a five-year maturity<\/p>\n<\/li>\n
- \nTwo-tranche structure:<\/p>\n
- \n
- \nTranche E, $265 million, used to refinance existing indebtedness<\/p>\n<\/li>\n
- \nTranche F, $35 million available for future growth initiatives<\/p>\n<\/li>\n<\/ul>\n<\/li>\n
- \nFixed interest rate with potential step-down based on leverage targets<\/p>\n<\/li>\n
- \nNo amortization, with principal due at maturity<\/p>\n<\/li>\n
- \nFlexible prepayment capability<\/p>\n<\/li>\n<\/ul>\n
\nConsistent with the terms of the existing debt, the amended and restated facility will be secured by a first-priority lien on substantially all assets of the company. The definitive documentation is substantially consistent with the company\u2019s prior credit agreement, with updates reflecting current market terms and the company\u2019s evolving and growing business.<\/p>\n
\nOaktree is a leading provider of debt and royalty financing for the global life sciences industry. Since 2020, funds managed by Oaktree have committed more than $6.0 billion across 44 investments for companies across the healthcare spectrum.<\/p>\n
\nA Form 8-K outlining the full terms of the credit facility will be filed with the Securities and Exchange Commission.<\/p>\n
About Oaktree<\/span><\/b><\/p>\n
\nOaktree is a leader among global investment managers specializing in alternative investments, with $223 billion in assets under management as of December 31, 2025. The firm emphasizes an opportunistic, value-oriented, and risk-controlled approach to investments in credit, equity, and real estate. The firm has more than 1,500 employees and offices in 26 cities worldwide. For additional information, please visit Oaktree\u2019s website at http:\/\/www.oaktreecapital.com\/<\/a>.<\/p>\n
About Establishment Labs<\/span><\/b><\/p>\n
\nEstablishment Labs Holdings Inc. is a global medical device company dedicated to improving women\u2019s health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 100 countries. With five million Motiva\u00ae devices delivered to plastic and reconstructive surgeons since 2010, the company\u2019s products have created a new standard for safety and patient satisfaction. The company\u2019s minimally invasive platform consists of Mia Femtech\u00ae, a unique minimally invasive experience for breast harmonization, and Preserv\u00e9\u2122, a breast tissue preserving and minimally invasive technology for primary breast augmentation and primary mastopexy augmentation. GEM\u00ae is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora\u00ae tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor\u2122 is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company\u2019s first biosensor Zen\u00ba\u2122, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2024 and FDA 21 CFR 820. Please visit our website for additional information at www.establishmentlabs.com<\/a>.<\/p>\n
Forward-Looking Statements<\/span><\/b><\/p>\n
\nThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cExchange Act\u201d). You can find many (but not all) of these statements by looking for words such as \u201capproximates,\u201d \u201cbelieves,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cestimates,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cintends to,\u201d \u201cwould,\u201d \u201cwill,\u201d \u201cmay\u201d or other similar expressions in this press release. Any statements that refer to projections of our future financial or operating performance, anticipated trends in our business, our goals, strategies, focus and plans, including related product development and commercialization and regulatory approvals, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, related to the company\u2019s performance are forward-looking statements. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995. We caution investors that any forward-looking statements presented in this report, or that we may make orally or in writing from time to time, are expressions of our beliefs and expectations based on currently available information at the time such statements are made. Such statements are based on assumptions, and the actual outcome will be affected by known and unknown risks, trends, uncertainties, and factors that are beyond our control. Although we believe that our assumptions are reasonable, we cannot guarantee future performance, and some will inevitably prove to be incorrect. As a result, our actual future results and the timing of events may differ from our expectations, and those differences may be material. Factors, among others, that could cause actual results and events to differ materially from those described in any forward-looking statements include risks and uncertainties relating to: our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product offerings; the rate of adoption of our products by healthcare providers or other customers; the success of our marketing initiatives; the safe and effective use of our products; our ability to protect our intellectual property; our future expansion plans and capital allocation; our ability to expand upon and\/or secure sources of credit or capital; our ability to develop and maintain relationships with qualified suppliers to avoid a significant interruption in our supply chains; our ability to attract and retain key personnel; our ability to scale our operations to meet market demands; the effect on our business of existing and new regulatory requirements; and other economic and competitive factors. These and other factors that could cause or contribute to actual results differing materially from our expectations include, among others, those risks and uncertainties discussed in the company’s annual report on Form 10-K filed on February 27, 2026, which risks and uncertainties may be updated in the future in other filings made by the company with the Securities and Exchange Commission. The risks included in those documents are not exhaustive, and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for us to predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We are not undertaking any obligation to update any forward-looking statements. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on known results and trends at the time they are made, to anticipate future results or trends.<\/p>\n
<\/p>\n
View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260430485118\/en\/<\/a><\/span><\/p>\n
\nInvestor\/Media Contact:
\n
Malavika William
\n
mwilliam@establishmentlabs.com<\/a><\/p>\nKEYWORDS:<\/b> New York United States North America<\/p>\n
INDUSTRY KEYWORDS:<\/b> Health Technology Health Surgery<\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260430485118\/en\/2790569\/3\/logo.jpg\"){kind=logo}
<\/td>\n<\/tr>\n